Prime Medicine, Inc. (NASDAQ: PRME) is a Healthcare company (Biotechnology) with a market capitalization of $699M. The Maz Rating grades it against the other companies in its sector.
Prime Medicine, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $3.84, Prime Medicine, Inc. trades at 99.2x sales and 81.2x book value. Over the last twelve months it generated about $7M of revenue and a net loss of $181M. It runs a gross margin of 48.8%, an operating margin of -2584.2% and a net margin of -2497.6%. It shows return on equity of -287.0%, return on invested capital of -97.2% and a free cash flow yield of -22.7%. On the balance sheet: a debt-to-equity ratio of 13.09 and a current ratio of 1.79. Over the past 52 weeks the share price ranged from $2.67 to $5.91, with a beta of 2.15.
Prime Medicine, Inc. does not currently pay a dividend.
10 Wall Street analyst ratings cover the stock: 7 Buy and 3 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.